- Home
- NMT vs CHRS Comparison
NMT vs CHRS Comparison
Compare NMT & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NMT
- CHRS
- Stock Information
- Founded
- NMT 1993
- CHRS 2010
- Country
- NMT United States
- CHRS United States
- Employees
- NMT N/A
- CHRS N/A
- Industry
- NMT Finance/Investors Services
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- NMT Finance
- CHRS Health Care
- Exchange
- NMT Nasdaq
- CHRS Nasdaq
- Market Cap
- NMT 109.8M
- CHRS 102.0M
- IPO Year
- NMT N/A
- CHRS 2014
- Fundamental
- Price
- NMT $11.37
- CHRS $0.88
- Analyst Decision
- NMT
- CHRS Buy
- Analyst Count
- NMT 0
- CHRS 3
- Target Price
- NMT N/A
- CHRS $4.68
- AVG Volume (30 Days)
- NMT 19.1K
- CHRS 1.4M
- Earning Date
- NMT 01-01-0001
- CHRS 08-11-2025
- Dividend Yield
- NMT 3.21%
- CHRS N/A
- EPS Growth
- NMT N/A
- CHRS N/A
- EPS
- NMT N/A
- CHRS N/A
- Revenue
- NMT N/A
- CHRS $272,251,000.00
- Revenue This Year
- NMT N/A
- CHRS N/A
- Revenue Next Year
- NMT N/A
- CHRS $142.61
- P/E Ratio
- NMT N/A
- CHRS $2.06
- Revenue Growth
- NMT N/A
- CHRS 19.87
- 52 Week Low
- NMT $9.05
- CHRS $0.66
- 52 Week High
- NMT $10.93
- CHRS $2.43
- Technical
- Relative Strength Index (RSI)
- NMT 34.58
- CHRS 47.28
- Support Level
- NMT $11.30
- CHRS $0.88
- Resistance Level
- NMT $11.52
- CHRS $1.15
- Average True Range (ATR)
- NMT 0.13
- CHRS 0.08
- MACD
- NMT -0.01
- CHRS -0.00
- Stochastic Oscillator
- NMT 16.28
- CHRS 18.26
About NMT Nuveen Massachusetts Quality Municipal Income Fund
Nuveen Massachusetts Quality Municipal Income Fund is a diversified closed-end management investment company. The Fund's objective seeks to provide current income exempt from both regular federal and Massachusetts income taxes by investing in a portfolio of municipal obligations issued by state and local government authorities within a single state or certain U.S. territories.
About CHRS Coherus BioSciences Inc.
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its strategy is to expand the use of LOQTORZI in NPC and advance the development of new indications for LOQTORZI in combination with both its pipeline candidates as well as its industry partners, driving synergies from proprietary combinations, including first-in-class anticancer agents. Its portfolio includes LOQTORZI, CHS-114, and Casdozokitug.